GT200600088A - Forma cristalina gamma de clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que la contienen - Google Patents

Forma cristalina gamma de clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que la contienen

Info

Publication number
GT200600088A
GT200600088A GT200600088A GT200600088A GT200600088A GT 200600088 A GT200600088 A GT 200600088A GT 200600088 A GT200600088 A GT 200600088A GT 200600088 A GT200600088 A GT 200600088A GT 200600088 A GT200600088 A GT 200600088A
Authority
GT
Guatemala
Prior art keywords
pharmaceutical compositions
compositions containing
crystal form
preparation procedure
ivabradine
Prior art date
Application number
GT200600088A
Other languages
English (en)
Inventor
Stephane Horvath
Marie-Noelle Auguste
Gerard Damien
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200600088(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200600088A publication Critical patent/GT200600088A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • G—PHYSICS
    • G04—HOROLOGY
    • G04F—TIME-INTERVAL MEASURING
    • G04F1/00—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers
    • G04F1/04—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers by movement or acceleration due to gravity
    • G04F1/06—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers by movement or acceleration due to gravity by flowing-away of a prefixed quantity of fine-granular or liquid materials, e.g. sand-glass, water-clock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
    • H04L51/21—Monitoring or handling of messages
    • H04L51/214—Monitoring or handling of messages using selective forwarding
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
    • H04L51/21—Monitoring or handling of messages
    • H04L51/212—Monitoring or handling of messages using filtering or selective blocking

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A LA NUEVA FORMA CRISTALINA GAMA DEL CLORHIDRATO DE IVABRADINA Y CUYA ESTRUCTURA SE OBSERVA EN EL PRESENTE RESUMEN. LA IVABRADINA SON DE UTILIDAD EN CUADROS DE ISQUEMIA MIOCÁRDICA TALES COMO ANGINA DE PECHO, EL INFARTO DE MIOCARDIO Y TRASTORNOS DEL RITMO.
GT200600088A 2005-02-28 2006-02-22 Forma cristalina gamma de clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que la contienen GT200600088A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0501989A FR2882555B1 (fr) 2005-02-28 2005-02-28 Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
GT200600088A true GT200600088A (es) 2006-10-24

Family

ID=34954955

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600088A GT200600088A (es) 2005-02-28 2006-02-22 Forma cristalina gamma de clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que la contienen

Country Status (42)

Country Link
US (3) US7361650B2 (es)
EP (1) EP1707562B1 (es)
JP (1) JP4628974B2 (es)
KR (1) KR100835447B1 (es)
CN (1) CN100402502C (es)
AP (1) AP1956A (es)
AR (1) AR052926A1 (es)
AT (1) ATE396974T1 (es)
BR (1) BRPI0600796B8 (es)
CA (1) CA2537400C (es)
CO (1) CO5770097A1 (es)
CR (1) CR8249A (es)
CU (1) CU23616B7 (es)
CY (1) CY1109010T1 (es)
DE (1) DE602006001312D1 (es)
DK (1) DK1707562T3 (es)
EA (1) EA008465B1 (es)
ES (1) ES2308689T3 (es)
FR (1) FR2882555B1 (es)
GE (1) GEP20084467B (es)
GT (1) GT200600088A (es)
HK (1) HK1096659A1 (es)
HR (1) HRP20080406T5 (es)
IL (1) IL173959A0 (es)
JO (1) JO2515B1 (es)
MA (1) MA28134A1 (es)
ME (1) ME02747B (es)
MY (1) MY158129A (es)
NO (1) NO338481B1 (es)
NZ (1) NZ545578A (es)
PE (1) PE20061142A1 (es)
PL (1) PL1707562T3 (es)
PT (1) PT1707562E (es)
RS (1) RS50598B (es)
SA (1) SA06270040B1 (es)
SG (1) SG125229A1 (es)
SI (1) SI1707562T1 (es)
TW (1) TWI314143B (es)
UA (1) UA86595C2 (es)
UY (1) UY29406A1 (es)
WO (1) WO2006092492A1 (es)
ZA (1) ZA200601764B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
EP2097383B1 (en) 2006-11-30 2012-02-08 Cadila Healthcare Limited Process for preparation of ivabradine hydrochloride
CN101353325B (zh) * 2007-07-27 2011-11-09 上海优拓医药科技有限公司 稳定型盐酸伊伐布雷定结晶及其制备方法
JP5632279B2 (ja) 2007-05-30 2014-11-26 アイエヌディー−スイフト ラボラトリーズ リミテッド 塩酸イバブラジンの調製方法及びポリモルフ
WO2010072409A1 (en) 2008-12-22 2010-07-01 Krka, D. D., Novo Mesto Process for preparation of ivabradine
CN101774969B (zh) 2009-01-13 2012-07-04 江苏恒瑞医药股份有限公司 硫酸伊伐布雷定及其i型结晶的制备方法
WO2010128525A2 (en) 2009-05-04 2010-11-11 Dinesh Shantilal Patel A formulation of ivabradine for treating the cardiovascular disease
SI23290A (sl) 2010-02-12 2011-08-31 Krka D.D., Novo Mesto Nove oblike ivabradin hidroklorida
HUP1000245A2 (en) 2010-05-07 2011-11-28 Richter Gedeon Nyrt Industrial process for the production ivabradin salts
TWI499587B (zh) * 2010-06-03 2015-09-11 Jiangsu Hengrui Medicine Co 硫酸伊伐佈雷定及其ｉ型結晶的製備方法
WO2012025940A1 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Polymorphic form of ivabradine hydrochloride and process for preparation thereof
WO2013017582A1 (en) 2011-08-02 2013-02-07 Sandoz Ag Acetone solvate of ivabradine hydrochloride
WO2013064427A1 (en) 2011-11-04 2013-05-10 Synthon Bv A process for making crystalline delta-form of ivabradine hydrochloride
EP2589594A1 (en) 2011-11-04 2013-05-08 Urquima S.A. Ivabradine hydrochloride Form IV
WO2013102919A1 (en) * 2011-11-14 2013-07-11 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
CN103183639B (zh) * 2011-12-30 2015-06-17 浙江京新药业股份有限公司 一种稳定的盐酸伊伐布雷定ii晶型及其制备方法
WO2014114341A1 (en) 2013-01-24 2014-07-31 Synthon Bv Process for making ivabradine
ITMI20130416A1 (it) * 2013-03-19 2014-09-20 Chemo Res S L Nuovo polimorfo del cloridrato di ivabradina e metodo per la sua preparazione
EP2781509B2 (en) * 2013-03-19 2023-06-14 Chemo Research, S.L. New polymorph of ivabradine hydrochloride and method for its preparation
CZ305096B6 (cs) 2013-10-02 2015-04-29 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice
WO2015001133A1 (en) 2013-12-12 2015-01-08 Synthon B.V. Pharmaceutical composition comprising amorphous ivabradine
SI2774606T1 (sl) 2014-02-14 2019-05-31 Synthon B.V. Farmacevtski sestavek, ki obsega polimorf IV ivabradin hidroklorida
CZ2014478A3 (cs) 2014-07-10 2015-09-16 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (R)-mandlové kyseliny a její farmaceutická kompozice
US11273162B2 (en) * 2016-04-01 2022-03-15 Mississippi State University Compositions and methods targeting HCN channels for breathing therapeutics
TR201703066A2 (tr) 2017-02-28 2018-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
EP3366282A1 (en) 2017-02-28 2018-08-29 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of ivabradine
US20230181472A1 (en) 2018-10-30 2023-06-15 Amgen Inc. Process of making ivabradine hydrochloride drug product
CA3161960A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef)
IT202000025312A1 (it) 2020-10-26 2022-04-26 Cambrex Profarmaco Milano S R L Processi per la preparazione di polimorfi di ivabradina hcl

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3119874A1 (de) * 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
US4490369A (en) * 1981-05-19 1984-12-25 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Benzazepine derivatives, their pharmaceutical compositions and method of use
FR2681862B1 (fr) * 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
CA2537400C (fr) 2009-12-15
IL173959A0 (en) 2006-07-05
CU23616B7 (es) 2011-01-27
WO2006092492A1 (fr) 2006-09-08
NO20060948L (no) 2006-08-29
DK1707562T3 (da) 2008-10-13
PL1707562T3 (pl) 2008-08-29
MY158129A (en) 2016-08-30
UA86595C2 (ru) 2009-05-12
HRP20080406T3 (en) 2008-09-30
ME02747B (me) 2010-05-07
BRPI0600796B1 (pt) 2019-02-19
SG125229A1 (en) 2006-09-29
BRPI0600796B8 (pt) 2021-05-25
RS50598B (sr) 2010-05-07
US20060194963A1 (en) 2006-08-31
CU20060037A7 (es) 2008-06-30
US7361650B2 (en) 2008-04-22
NZ545578A (en) 2007-02-23
JP2006241156A (ja) 2006-09-14
HRP20080406T5 (en) 2008-11-30
TWI314143B (en) 2009-09-01
ES2308689T3 (es) 2008-12-01
EA200600320A1 (ru) 2006-08-25
CR8249A (es) 2008-01-21
AP2006003521A0 (en) 2006-02-28
EP1707562A1 (fr) 2006-10-04
CA2537400A1 (fr) 2006-08-28
CN100402502C (zh) 2008-07-16
FR2882555B1 (fr) 2007-05-04
JP4628974B2 (ja) 2011-02-09
PE20061142A1 (es) 2006-12-30
US7867996B2 (en) 2011-01-11
KR20060095499A (ko) 2006-08-31
EP1707562B1 (fr) 2008-05-28
US20080153803A1 (en) 2008-06-26
US20090318417A1 (en) 2009-12-24
UY29406A1 (es) 2006-07-31
SA06270040B1 (ar) 2010-03-23
CO5770097A1 (es) 2007-06-29
MA28134A1 (fr) 2006-09-01
BRPI0600796A (pt) 2007-08-14
NO338481B1 (no) 2016-08-22
AU2006200857A1 (en) 2010-01-28
CY1109010T1 (el) 2014-07-02
ATE396974T1 (de) 2008-06-15
PT1707562E (pt) 2008-07-08
KR100835447B1 (ko) 2008-06-09
JO2515B1 (en) 2010-03-17
HK1096659A1 (en) 2007-06-08
DE602006001312D1 (de) 2008-07-10
AR052926A1 (es) 2007-04-11
SI1707562T1 (sl) 2008-10-31
AP1956A (en) 2009-02-18
GEP20084467B (en) 2008-08-25
CN1827602A (zh) 2006-09-06
EA008465B1 (ru) 2007-06-29
ZA200601764B (en) 2007-05-30
TW200640872A (en) 2006-12-01
FR2882555A1 (fr) 2006-09-01

Similar Documents

Publication Publication Date Title
GT200600088A (es) Forma cristalina gamma de clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que la contienen
GT200600085A (es) Forma cristalina beta-d del clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que la contienen
UY29407A1 (es) Forma cristalina gamma-d del clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmaceuticas que la contienen.
UY29405A1 (es) Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la continen.
GT200600448A (es) Forma cristalina delta-d de clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que la contienen
GT200600450A (es) Forma cristalina delta de clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que la contienen
PE20121442A1 (es) Derivados de oxindol sustituido y composiciones farmaceuticas que los comprenden
CL2013003598A1 (es) Compuestos derivados de benzooxazepinona, moduladores de canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades seleccionadas de arritmias, insuficiencia cardiaca, angina, infarto al miocardio, diabetes, entre otras
PE20120428A1 (es) Composicion farmaceutica solida que comprende amlodipina y losartan
BR122013025375B8 (pt) compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas
CL2014002386A1 (es) Compuesto inhibidor de cinasa de fosfoinositida 3 en forma anhidra cristalina solida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento o prevencion de enfermedades tales como epoc, asma, entre otras.
GT201300165A (es) Compuestos y su uso como inhibidores de bace
CL2011002197A1 (es) Compuestos derivados de piperidinas sustituidas; composición farmacéutica que los comprende; y su uso como inhibidores de los receptores ccr3 para la prevención y/o el tratamiento de enfermedades tales como asma, alergias, epoc, artritis reumatoide y aterosclerosis.
GT200600347A (es) Nueva formula cristalina iii de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
ECSP11011057A (es) Ácidos naftilacéticos
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения
ECSP109961A (es) Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica
EA201071183A1 (ru) Безводная кристаллическая форма малеата орвепитанта
CO6612268A2 (es) Heterobiaril-ciclohexil-tetraazabenzo[e]azulenos
MX352548B (es) Compuestos disustituidos de tetrahidrofuranilo como antagonistas de receptor de bradiquinina b1.
CY1116739T1 (el) Μεθοδος συνθεσης και κρυσταλλικη μορφη του υδροχλωρικου 4-{3-[cis-εξαϋδροκυκλοπεντα[c]πυρρολ-2(1η)-υλ] προποξυ} βενζαμιδιου καθως και η συνδεομενη ελευθερη βαση και οι φαρμακευτικες συνθεσεις οι οποιες τις περιεχουν
UY29517A1 (es) Nueva clase de 4-lactama benzonitrilos, composiciones farmacéuticas que los contienen y aplicaciones
PE20130004A1 (es) Formulaciones farmaceuticas solidas de ramipril y besilato de amlodipino y su preparacion
ATE546448T1 (de) Urotensin-ii-rezeptorantagonisten
PE20090367A1 (es) Formas cristalinas a y b del compuesto 3-(2r-tetrahidrofuril-metil)-2-tioxantina